{
    "clinical_study": {
        "@rank": "163257", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A - B", 
                "arm_group_type": "Experimental", 
                "description": "Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours."
            }, 
            {
                "arm_group_label": "Treatment B - A", 
                "arm_group_type": "Active Comparator", 
                "description": "Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to establish Bioequivalence (BE) of 2 different\n      formulations of the 2 mg/24 hr (10 cm^2) Rotigotine transdermal patches in Chinese subjects."
        }, 
        "brief_title": "Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Bioequivalence will be concluded if the 90 % Confidence Intervals (CIs) for the ratio\n      Treatment A/Treatment B are fully included in the acceptance range from 0.8-1.25 for\n      AUC(0-t) and AUC, and within the acceptance range from 0.7 to 1.43 for Cmax."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An Independent Ethics Committee (IEC) approved written Informed Consent form is\n             signed and dated by the subject\n\n          -  Subject is considered reliable and capable of adhering to the protocol, visit\n             schedule, and patch application according to the judgment of the investigator\n\n          -  Subject is willing and able to comply with all study requirements\n\n          -  Subject is Chinese (with all 4 grandparents being of Chinese origin, as well), male,\n             and aged between 18 and 40 years (inclusive)\n\n          -  Subject is healthy (no clinically significant findings in any of the investigations\n             at the Eligibility Assessment (EA))\n\n          -  Subject has a body mass index between 19 kg/m\u00b2 and 24 kg/m\u00b2 (inclusive), and a body\n             weight greater than or equal to 50 kg\n\n          -  Subject agreed to practice a medically accepted method of contraception (eg, condom,\n             spermicide) unless sexually abstinent for the duration of the study and up to 3\n             months after the final patch application\n\n        Exclusion Criteria:\n\n          -  Subject has previously participated in this study or subject has previously been\n             assigned to treatment in a Rotigotine study\n\n          -  Subject has participated in another study of an Investigational Medicinal Product\n             (IMP) (or a medical device) within the previous 3 months or is currently\n             participating in another study of an IMP (or a medical device)\n\n          -  Subject has a history of diagnosis, counseling, or treatment for chronic alcohol or\n             drug abuse within the previous 2 years\n\n          -  Subject has a known clinically significant allergy or known or suspected clinically\n             significant drug hypersensitivity to any components of the IMP or comparable drugs\n             that, in the opinion of the investigator, could jeopardize or would compromise the\n             subject's ability to participate in this study\n\n          -  Subject has lifetime history of suicide attempt\n\n          -  Subject has a history of significant skin hypersensitivity to adhesives or other\n             transdermal products or has recently unresolved contact dermatitis\n\n          -  Subject has an medical or psychiatric condition that, in the opinion of the\n             investigator, could jeopardize or would compromise the subject's ability to\n             participate in this study\n\n          -  Subject has a history or present condition of epilepsy and/or seizures\n\n          -  Subject has a history or present condition of an atopic or eczematous dermatitis,\n             psoriasis, and/or an active skin disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070796", 
            "org_study_id": "PD0011"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A - B", 
                    "Treatment B - A"
                ], 
                "description": "Treatment A:\nRotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.", 
                "intervention_name": "Rotigotine PR2.2.1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment A - B", 
                    "Treatment B - A"
                ], 
                "description": "Treatment B:\nRotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours.", 
                "intervention_name": "Rotigotine PR2.1.1", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "N 0437"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rotigotine", 
            "Transdermal Patch", 
            "Bioequivalence"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hong Kong", 
                    "country": "China"
                }, 
                "name": "1"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations", 
        "overall_contact": {
            "last_name": "UCB Clinical Trial Call Center", 
            "phone": "+1 877 822 9493"
        }, 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Hong Kong: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration (AUC(0-t))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application."
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero up to Infinity (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "The maximum plasma concentration of unconjugated Rotigotine (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070796"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg) (AUC(0-t) norm (apparent dose))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg) (AUC(0-t) norm (BW))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero up to infinity normalized by apparent dose (mg) (AUCnorm (apparent dose))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from zero up to infinity normalized by body weight (kg) (AUCnorm (BW))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Maximum plasma concentration of unconjugated Rotigotine normalized by apparent dose (Cmax, norm (apparent dose))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Maximum plasma concentration of unconjugated Rotigotine normalized by body weight (Cmax, norm (BW))", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Time to reach a maximum plasma concentration of unconjugated Rotigotine after patch application (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Mean residence time (MRT)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Rate constant of elimination (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Relative bioavailability calculated based on Cmax (fCmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Relative bioavailability calculated based on AUC (fAUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }, 
            {
                "measure": "Apparent total body clearance (CL/f)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken predose, and at 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr (immediately prior to patch removal in the morning of Day 2), 25 hr, 26 hr, 28 hr, 30 hr, 32 hr, 36 hr, 40 hr, and 48 hr after patch application"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Pharma SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}